Cargando…

SUMO pathway inhibition targets an aggressive pancreatic cancer subtype

OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) still carries a dismal prognosis with an overall 5-year survival rate of 9%. Conventional combination chemotherapies are a clear advance in the treatment of PDAC; however, subtypes of the disease exist, which exhibit extensive resistance to such the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biederstädt, Alexander, Hassan, Zonera, Schneeweis, Christian, Schick, Markus, Schneider, Lara, Muckenhuber, Alexander, Hong, Yingfen, Siegers, Gerrit, Nilsson, Lisa, Wirth, Matthias, Dantes, Zahra, Steiger, Katja, Schunck, Kathrin, Langston, Steve, Lenhof, H-P, Coluccio, Andrea, Orben, Felix, Slawska, Jolanta, Scherger, Anna, Saur, Dieter, Müller, Stefan, Rad, Roland, Weichert, Wilko, Nilsson, Jonas, Reichert, Maximilian, Schneider, Günter, Keller, Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Pancreas
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398468/ https://www.ncbi.nlm.nih.gov/pubmed/32001555 http://dx.doi.org/10.1136/gutjnl-2018-317856

Ejemplares similares

The SUMO pathway in pancreatic cancer: insights and inhibition
por: Schneeweis, Christian, et al.
Publicado: (2020)

MTOR inhibitor-based combination therapies for pancreatic cancer
por: Hassan, Zonera, et al.
Publicado: (2018)

A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer
por: Kloesch, Bernhard, et al.
Publicado: (2022)

Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma
por: Schick, Markus, et al.
Publicado: (2022)

Differences in receipt of multimodality therapy by race, insurance status, and socioeconomic disadvantage in patients with resected pancreatic cancer
por: Hao, Scarlett, et al.
Publicado: (2022)

Genome-wide association study identifies inversion in the CTRB1-CTRB2 locus to modify risk for alcoholic and non-alcoholic chronic pancreatitis
por: Rosendahl, Jonas, et al.
Publicado: (2018)

Human pluripotent stem cell-derived acinar/ductal organoids generate human pancreas upon orthotopic transplantation and allow disease modelling
por: Hohwieler, Meike, et al.
Publicado: (2017)

Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer
por: Gout, Johann, et al.
Publicado: (2021)

Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition
por: Schneeweis, Christian, et al.
Publicado: (2022)

Impact of Tumor Grade on Prognosis in Pancreatic Cancer: Should We Include Grade in AJCC Staging?
por: Wasif, Nabil, et al.
Publicado: (2010)

Autoimmune pancreatitis results from loss of TGFβ signalling in S100A4-positive dendritic cells
por: Boomershine, C S, et al.
Publicado: (2009)

Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)
por: Dahan, Laetitia, et al.
Publicado: (2010)

Fatty acid ethyl ester synthase inhibition ameliorates ethanol-induced Ca(2+)-dependent mitochondrial dysfunction and acute pancreatitis
por: Huang, Wei, et al.
Publicado: (2014)

Targeting mTOR dependency in pancreatic cancer
por: Morran, Douglas C, et al.
Publicado: (2014)

Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis
por: Hart, Phil A, et al.
Publicado: (2013)

Opportunities of improvement in the management of pancreatic and periampullary tumors: Prospective evaluation of outcome from a multidisciplinary research program
por: Nordby, Tom, et al.
Publicado: (2013)

Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages
por: Yu, Jun, et al.
Publicado: (2015)

MRI with hyperpolarised [1-(13)C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model
por: Serrao, Eva M, et al.
Publicado: (2016)

The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells
por: Cioffi, Michele, et al.
Publicado: (2015)

Caffeine protects against experimental acute pancreatitis by inhibition of inositol 1,4,5-trisphosphate receptor-mediated Ca(2+) release
por: Huang, Wei, et al.
Publicado: (2017)

Mechanism of mitochondrial permeability transition pore induction and damage in the pancreas: inhibition prevents acute pancreatitis by protecting production of ATP
por: Mukherjee, Rajarshi, et al.
Publicado: (2016)

Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer
por: Mahajan, Ujjwal M, et al.
Publicado: (2016)

GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer
por: Martinelli, Paola, et al.
Publicado: (2017)

Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms
por: Yu, Jun, et al.
Publicado: (2017)

Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
por: Zhang, Yaqing, et al.
Publicado: (2017)

Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2018)

Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility
por: Knudsen, Erik S, et al.
Publicado: (2018)

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer
por: Hessmann, E, et al.
Publicado: (2018)

Targeting both tumour-associated CXCR2(+) neutrophils and CCR2(+) macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma
por: Nywening, Timothy M, et al.
Publicado: (2018)

Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer
por: Goehrig, Delphine, et al.
Publicado: (2019)

Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
por: Raj, Deepak, et al.
Publicado: (2019)

Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
por: Chou, Angela, et al.
Publicado: (2018)

Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia
por: Singhi, Aatur D, et al.
Publicado: (2018)

Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis
por: de la Iglesia-García, Daniel, et al.
Publicado: (2017)

SWI/SNF component ARID1A restrains pancreatic neoplasia formation
por: Wang, Sam C, et al.
Publicado: (2019)

Factors affecting the rates of adherence to surveillance recommendations for incidental pancreatic cystic lesions in a large urban safety net hospital
por: Canakis, Andrew, et al.
Publicado: (2020)

Development of a volumetric pancreas segmentation CT dataset for AI applications through trained technologists: a study during the COVID 19 containment phase
por: Suman, Garima, et al.
Publicado: (2020)

Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer
por: Gaiser, Rogier Aäron, et al.
Publicado: (2019)

Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system
por: Hong, Xiafei, et al.
Publicado: (2020)

Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications
por: Luchini, Claudio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jsmqld4m997s6adk7nsko9erne